Recent developments highlight the potential of antibody-drug conjugates (ADCs ... presented by major histocompatibility complexes (MHC). These methods complement existing therapies but face ...

Containing mutations in the MHC α3 domain that ablate CD8 binding; can be used to quantitate and to sort CD8-independent T cells. Developing high-affinity soluble antibody molecules endowed with a TCR ...

Macbecin II was identified as a compound that upregulates MHC-I expression, enhancing immune-mediated cancer cell killing. In ...

While it's known that major histocompatibility complex class I (MHC-I) plays a central role ... trigger the body's immune system to produce antibodies—and explore ways to use the antigens ...

The study revealed that only MHC-II levels correlated significantly with patient outcomes, while none of the five PD-L1 antibodies tested showed statistical significance. Ignite Proteomics ...

These solid-phase tests can simultaneously detect and distinguish MHC class I and class II antibodies, thus providing information that was previously problematic to obtain. HLA class I antibodies ...

The CD8-mediated binding can usually be blocked by inclusion of select CD8 monoclonal antibodies that block the interaction ... The suggested titer for the MHC tetramer reagent is 1:200. Add 25ml of ...

In addition, the association of CD3 with the TCR–peptide–MHC complex transmits the activation ... After stimulation of the TCR with an antibody, fewer CD3ɛ mutant T cells showed ERK ...